Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613080 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT00613080 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 79 participants.
The verdict
NCT00613080, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying the side effects and how well giving combination chemotherapy together with intensity-modulated radiation therapy works in treating patients undergoing surgery for locally advanced rectal cancer.
Interventions
- DRUG FOLFOX
- DRUG oxaliplatin
- DRUG capecitabine
- RADIATION radiation therapy
- PROCEDURE resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2008-04 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00613080
The ClinicalTrials.gov registry entry for NCT00613080 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which FOLFOX is the first listed.
NCT00613080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00613080 about?
NCT00613080 is a clinical study titled "Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to...
What is the current status of trial NCT00613080?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2008-04. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00613080?
The interventions under investigation include: FOLFOX (DRUG), oxaliplatin (DRUG), capecitabine (DRUG), radiation therapy (RADIATION), resection (PROCEDURE).
Who is sponsoring clinical trial NCT00613080?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.